INVESTMENT HIGHLIGHTS
- Cell-based therapies and products platform
- Rapid lab expansion and strong market position
- Near term value drivers and 3 profitable therapies in market already
- First movers in using stem cell for spinal cord cell therapy
- Robust discovery pipeline of internal research and external collaboration
- International team of management, scientist and doctors (scientific advisory board and world leaders)
Investor Relations Contact:
Judyanna Yu
Re-Stem Biotech
judyanna@restembiotech.com
